The case describes the predicaments faced by Immunovaccine (IMV), a small biotechnology company founded in Halifax, Canada. The business has seen early success in the effectiveness of its technology in animal health and is searching for ways to manipulate the possibility of its technology more broadly and especially in human health.
The business's challenges are presented in the context of the evolving relationship between the biotechnology and pharmaceutical sectors. The case depicts a variety of issues the company face around 2008, shortly after the innovative president and CEO has taken over. It then offer details on strategy formulation and implementation under the novel CEO.
PUBLICATION DATE: October 13, 2010 PRODUCT #: 910M72-PDF-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
Genzymes CSR Dilemma: How to Play its HAND
Sowers Action (A): The First Ten Yards
Pedigree vs. Grit: Predicting Mutual Fund Manager Performance
The Elcer Products Transaction: Confidential Information for Euro Elektrische Keramische Vorrichtungen (Euro EKV) GmbH
The Elcer Products Transaction: Confidential Information for Elcer Products Division President
The War for Management Talent in China: LEOX Design Partnership
Monster Networking
NFL Club Business Management
Cisco: Early if Not Elegant (B)-Epilogue
How to Address the Gray Market Threat Using Price Coordination
